Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX Plus Radiotherapy in CA19-9-normal Advanced Pancreatic Cancer
NCT06249321Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan, folinic acid and fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University. Primary endpoint: Progression-Free Survival. Started Apr 2024; status: recruiting.
02
Drugs
oxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06249321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249321.